Edition:
United States

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

17.76EUR
17 Aug 2018
Change (% chg)

€0.06 (+0.34%)
Prev Close
€17.70
Open
€18.00
Day's High
€18.02
Day's Low
€17.76
Volume
52,351
Avg. Vol
79,319
52-wk High
€21.30
52-wk Low
€16.36

Chart for

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.54
Market Cap(Mil.): €15,104.40
Shares Outstanding(Mil.): 687.55
Dividend: 0.20
Yield (%): 0.83

Financials

  GRLSbn.MC Industry Sector
P/E (TTM): 23.83 28.29 30.45
EPS (TTM): 1.03 -- --
ROI: 6.81 12.92 12.63
ROE: 18.65 14.94 14.82

Healthcare firm Grifols S.A. wins U.S. antitrust nod to buy Biotest US Corp

WASHINGTON Global healthcare company, Grifols S.A. , which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

Aug 01 2018

Healthcare firm Grifols S.A. wins US antitrust nod to buy Biotest US Corp

WASHINGTON, Aug 1 Global healthcare company, Grifols S.A., which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

Aug 01 2018

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Firday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

May 25 2018

BRIEF-Grifols Expands Its Blood Typing Solutions Portfolio In US With Antisera Reagents

* GRIFOLS EXPANDS ITS BLOOD TYPING SOLUTIONS PORTFOLIO IN THE UNITED STATES WITH ANTISERA REAGENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 14 2018

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

May 03 2018

BRIEF-Grifols Concludes Experimental Phase Of Clinical Trial On Alzheimer

* SAYS CONCLUDES EXPERIMENTAL PHASE OF AMBAR, A CLINICAL TRIAL ON ALZHEIMER'S DISEASE

Mar 22 2018

BRIEF-Grifols To Buy German Pharmaceutical Company Haema For 220 Mln Euros

* SAYS REACHES DEAL WITH ATON GMBH TO BUY 100 PERCENT OF HAEMA AG FOR 220 MILLION EUROS ON A DEBT FREE BASIS ‍​ Source text for Eikon:

Mar 20 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Mar 14 2018

BRIEF-Grifols Announces New Agreement With Henry Schein To Distribute Normal Saline Solution In U.S.

* GRIFOLS - ANNOUNCES NEW AGREEMENT WITH HENRY SCHEIN TO DISTRIBUTE NORMAL SALINE SOLUTION IN THE U.S.

Mar 05 2018

Spanish stocks - Factors to watch on Wednesday

The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Feb 28 2018

Earnings vs. Estimates